Case Study

# How Ambry Genetics governs clinical data and builds a PHI-free environment with Collate®

![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27310%27%20height=%27400%27/%3e)![Form Header](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)

![Form Header](/_next/image?url=%2Fimages%2Febook%2Fambry-case-study-form-header.webp&w=640&q=75)

Get your Copy

In clinical diagnostics, a patient case is rarely static. Variant interpretations, gene-disease relationships, reference builds, and the commercial details around an order all change over time, while CAP, CLIA, HIPAA, and FDA obligations set a high bar for how that data can be stored, shared, and traced.

Learn how Ambry Genetics, a clinical genetic testing lab now part of Tempus AI with more than three decades of hereditary cancer data, built a clinical data product lifecycle on Collate's managed OpenMetadata service and stood up a governed, de-identified environment free of Protected Health Information, including:

*   How Ambry defined a de-identified environment across six PHI-free MySQL databases and 11,000+ data assets, with 29 PHI classification tags applied across all source assets
*   How Collate's tag, lineage, profiler, and auto-classification automations track identified PHI elements and reconcile the PHI-free databases against production
*   The clinical data product lifecycle Ambry uses, from one-line registration through metadata operations, quality dimensions, and regulatory adherence